Alectinib-associated pneumoperitoneum in stage IV non-small cell lung cancer - A case report.

ABSTRACT:

Introduction and importance

Alectinib, a highly potent, highly selective, brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor is now the first line therapy for patients with metastatic ALK-positive non small cell lung cancer (NSCLC).

Case presentation

We report a rare case of pneumoperitoneum following alectinib initiation for metastatic non small cell lung cancer in a 74-year-old African American female. Patient developed abdominal pain approximately 2 weeks after starting alectinib. She was hemodynamically stable, and imaging revealed pneumoperitoneum. Patient was successfully managed non-operatively.

Clinical discussion

Gastrointestinal perforation presenting as pneumoperitoneum is a very rare complication of alectinib. To our knowledge our patient is only t

SUBMITTER: Maina RM 

PROVIDER: S-EPMC9577531 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature